Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer
Selpercatinib, a RET kinase inhibitor, is an effective treatment for patients with medullary thyroid cancer with RET mutations. In this paper, we present the case of a 62-year-old man with ectopic Cushing’s syndrome due to medullary thyroid cancer who received treatment with selpercatinib. Six month...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/5/282 |
| _version_ | 1797500516915216384 |
|---|---|
| author | Oskar Ragnarsson Marta Piasecka Andreas Hallqvist |
| author_facet | Oskar Ragnarsson Marta Piasecka Andreas Hallqvist |
| author_sort | Oskar Ragnarsson |
| collection | DOAJ |
| description | Selpercatinib, a RET kinase inhibitor, is an effective treatment for patients with medullary thyroid cancer with RET mutations. In this paper, we present the case of a 62-year-old man with ectopic Cushing’s syndrome due to medullary thyroid cancer who received treatment with selpercatinib. Six months later, all the cushingoid features had resolved, and s-calcitonin had decreased from 580 pmol/L to 3.5 pmol/L (normal < 3). After further 6 months, s-calcitonin had normalized (1.5 pmol/L), and radiological evaluation showed a profound tumour volume reduction. We are aware of two other cases where treatment with selpercatinib has also been successful. Thus, selpercatinib may be a promising treatment alternative in patients with ectopic Cushing’s syndrome due to medullary thyroid cancer, especially when other treatment options are ineffective or not tolerated. |
| first_indexed | 2024-03-10T03:03:59Z |
| format | Article |
| id | doaj.art-8cb51c6ec74442ab9fd0b180369fd7a7 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T03:03:59Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-8cb51c6ec74442ab9fd0b180369fd7a72023-11-23T10:37:15ZengMDPI AGCurrent Oncology1198-00521718-77292022-05-012953494349810.3390/curroncol29050282Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid CancerOskar Ragnarsson0Marta Piasecka1Andreas Hallqvist2Department of Endocrinology, Sahlgrenska University Hospital, SE-41302 Gothenburg, SwedenDepartment of Endocrinology, Sahlgrenska University Hospital, SE-41302 Gothenburg, SwedenDepartment of Oncology, Sahlgrenska University Hospital, SE-41302 Gothenburg, SwedenSelpercatinib, a RET kinase inhibitor, is an effective treatment for patients with medullary thyroid cancer with RET mutations. In this paper, we present the case of a 62-year-old man with ectopic Cushing’s syndrome due to medullary thyroid cancer who received treatment with selpercatinib. Six months later, all the cushingoid features had resolved, and s-calcitonin had decreased from 580 pmol/L to 3.5 pmol/L (normal < 3). After further 6 months, s-calcitonin had normalized (1.5 pmol/L), and radiological evaluation showed a profound tumour volume reduction. We are aware of two other cases where treatment with selpercatinib has also been successful. Thus, selpercatinib may be a promising treatment alternative in patients with ectopic Cushing’s syndrome due to medullary thyroid cancer, especially when other treatment options are ineffective or not tolerated.https://www.mdpi.com/1718-7729/29/5/282medullary thyroid cancerectopic Cushing’s syndromeparaneoplastic syndromehypercortisolism |
| spellingShingle | Oskar Ragnarsson Marta Piasecka Andreas Hallqvist Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer Current Oncology medullary thyroid cancer ectopic Cushing’s syndrome paraneoplastic syndrome hypercortisolism |
| title | Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer |
| title_full | Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer |
| title_fullStr | Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer |
| title_full_unstemmed | Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer |
| title_short | Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer |
| title_sort | successful treatment with selpercatinib for ectopic cushing s syndrome due to medullary thyroid cancer |
| topic | medullary thyroid cancer ectopic Cushing’s syndrome paraneoplastic syndrome hypercortisolism |
| url | https://www.mdpi.com/1718-7729/29/5/282 |
| work_keys_str_mv | AT oskarragnarsson successfultreatmentwithselpercatinibforectopiccushingssyndromeduetomedullarythyroidcancer AT martapiasecka successfultreatmentwithselpercatinibforectopiccushingssyndromeduetomedullarythyroidcancer AT andreashallqvist successfultreatmentwithselpercatinibforectopiccushingssyndromeduetomedullarythyroidcancer |